PDB-6dq4: LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR GSK-J1 手法: X-RAY DIFFRACTION / 解像度: 1.392 Å
PDB-6dq5: LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N43 i.e. 3-((6-(4-acryloyl-1,4-diazepan-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid 手法: X-RAY DIFFRACTION / 解像度: 1.89 Å
PDB-6dq6: LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N44 i.e. 3-((2-(pyridin-2-yl)-6-(4-(vinylsulfonyl)-1,4-diazepan-1-yl)pyrimidin-4-yl)amino)propanoic acid 手法: X-RAY DIFFRACTION / 解像度: 1.587 Å
PDB-6dq8: LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N49 i.e. 2-((2-chlorophenyl)(2-(1-methylpyrrolidin-2-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid 手法: X-RAY DIFFRACTION / 解像度: 1.46 Å
PDB-6dq9: Linked KDM5A JMJ Domain Bound to the Covalent Inhibitor N69 i.e. [2-((3-acrylamidophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid] 手法: X-RAY DIFFRACTION / 解像度: 1.748 Å
PDB-6dqa: Linked KDM5A JMJ Domain Bound to Inhibitor N70 i.e.[2-((3-aminophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid] 手法: X-RAY DIFFRACTION / 解像度: 1.888 Å
PDB-6dqb: LINKED KDM5A JMJ DOMAIN FORMING COVALENT BOND TO INHIBITOR N71 i.e. 2-((3-(4-(dimethylamino)but-2-enamido)phenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid 手法: X-RAY DIFFRACTION / 解像度: 1.791 Å